Clinical Trials - A Scorecard for Clinical Trial Investigations in 2020
Summary
The purpose of this report is to provide insight into the clinical trial landscape for 2020, an analyses of the main features of these trials, and quarterly trends, where relevant.
This report provides an overview of global clinical trials with a start date between January 1, 2020 and December 31, 2020. Due to the COVID-19 pandemic, many of these trials have either been interrupted or disrupted.
Scope
Reasons to Buy
Summary
The purpose of this report is to provide insight into the clinical trial landscape for 2020, an analyses of the main features of these trials, and quarterly trends, where relevant.
This report provides an overview of global clinical trials with a start date between January 1, 2020 and December 31, 2020. Due to the COVID-19 pandemic, many of these trials have either been interrupted or disrupted.
Scope
- The clinical trials data used for these analyses were extracted from the publisher's Clinical Trials Database. The data included clinical trials with a start date between January 1, 2020 to December 31, 2020, which were captured in the database as of February 13, 2021.
- The trials were analyzed and segmented by phase, single versus multinational trials, geography, sponsor type (industry versus non-industry), therapy area, indication, top sponsors, molecule type, and top drug trials.
- Additional analyses were conducted for trials that were completed or terminated, as well as COVID-19 trials in all recruitment statuses. COVID-19 was the top indication for clinical trials at the time when the data were locked for analysis.
Reasons to Buy
- Understand the global clinical trial landscape in 2020
- The trends of completed clinical trials in 2020
- The trends of clinical trial terminations in 2020
- A closer look at COVID-19 clinical trials in 2020
- Understand the changes in 2020 and the impact for 2021
Table of Contents
- Executive Summary
- Introduction
- Report Scope
- Methodology
- Global Clinical Trial Landscape in 2020
- Completed Trials in 2020
- Clinical Trial Terminations in 2020
- Spotlight on COVID-19 Clinical Trials for 2020
- Key Findings
- Appendix
List of Tables
- Table 1: Top Industry-Sponsored Innovator Drugs in Clinical Development by Primary Intervention for 2020
- Table 2: Top Industry-Sponsored Biosimilar Drugs in Clinical Development by Primary Intervention for 2020
- Table 3: Top Terminated Drugs in Clinical Development, by Clinical Trial Count
List of Figures
- Figures 1 & 2: Clinical Trials by Sponsor Type, Status and Initiation/Completion
- Figures 3 & 4: Clinical Trials, by Phase and Sponsor Type
- Figure 5: Single Country and Multinational Trials
- Figure 6: Clinical Trials Regions, by Phase
- Figure 7: Clinical Trials Regions, by Phase and Distribution
- Figure 8: Planned Clinical Trials Country, by Phase
- Figure 9: Clinical Trials Country, by Phase and Distribution
- Figure 10: Clinical Trials Top Therapy Areas, by Phase
- Figure 11: Clinical Trials Top Therapy Areas, by Phase and Distribution
- Figure 12: Pivotal/Registration Clinical Trials Top Therapy Areas, by Phase
- Figure 13: Clinical Trials Top Indications, by Phase
- Figure 14: Clinical Trials Top Indications, by Phase and Distribution
- Figure 15: Pivotal/Registration Clinical Trials Top Indications, by Phase
- Figure 16: Clinical Trials Top Industry Sponsors, by Phase
- Figure 17: Clinical Trials Top Non-Industry Sponsors, by Phase
- Figure 18: Pivotal/Registration Clinical Trials Top Industry Sponsors, by Phase
- Figure 19: Completed Trials Endpoint Status, by Sponsor Type
- Figure 20 & 21: Completed Trials Endpoint Status, by Sponsor Type and Phase
- Figure 22: Pivotal/Registration Industry Sponsored Trials Endpoint Status, by Phase
- Figure 23: Completed Clinical Trials Top Sponsors, by Phase
- Figure 24: Top Completed Drugs, by Clinical Trial Count
- Figure 25 & 26: Terminated Trials, by Phase and Reason
- Figure 27: Terminated Clinical Trials Top Therapy Areas, by Phase
- Figure 28: Terminated Clinical Trials Top Indications, by Phase
- Figure 29: Terminated Clinical Trials for Sponsors, by Phase
- Figure 30: Clinical Trials for COVID-19, by Status and Sponsor Type
- Figure 31: Clinical Trials for COVID-19, by Phase
- Figure 32: Clinical Trials for COVID-19, by Top Industry Sponsors
- Figure 33: Clinical Trials for COVID-19, by Top Non-Industry Sponsors
- Figure 34 & 35: Clinical Trials for COVID-19, by Molecule Type and Phase
- Figure 36 & 37: Reasons for Trial Disruptions
